{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05962476",
            "orgStudyIdInfo": {
                "id": "HUM00231771"
            },
            "organization": {
                "fullName": "University of Michigan",
                "class": "OTHER"
            },
            "briefTitle": "Transcutaneous Vibro-Acoustic Therapy in Parkinson Disease",
            "officialTitle": "Transcutaneous Vibro-Acoustic Therapy in Parkinson Disease",
            "therapeuticArea": [
                "Neurology"
            ],
            "study": "transcutaneous-vibro-acoustic-therapy-in-parkinson-disease"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-08",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-08-09",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-07",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-07",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-06-29",
            "studyFirstSubmitQcDate": "2023-07-24",
            "studyFirstPostDateStruct": {
                "date": "2023-07-27",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-08-10",
            "lastUpdatePostDateStruct": {
                "date": "2023-08-14",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Prabesh Kanel",
                "investigatorTitle": "Research Investigator",
                "investigatorAffiliation": "University of Michigan"
            },
            "leadSponsor": {
                "name": "University of Michigan",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "Small exploratory pilot study to assess effects of a transcutaneous vibro-acoustic therapy device (Apollo Neuro) in people with Parkinson's disease (PD).",
            "detailedDescription": "The overarching goal of this study is to investigate changes in anxiety, nighttime heart rate variability, and fear of falling in people with PD before and after 3-months usage of a transcutaneous vibro-acoustic therapy device. Positive findings in this small exploratory pilot trial may support future studies of transcutaneous vibro-acoustic therapy for individuals with PD."
        },
        "conditionsModule": {
            "conditions": [
                "Parkinson Disease"
            ],
            "keywords": [
                "transcutaneous vibro-acoustic therapy",
                "anxiety"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "NA"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 10,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Parkinson's Disease",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will use the vibro-acoustic device 90-120 days for 6 hours at night on the Apollo Neuro setting \"Sleep and Renew\".",
                    "interventionNames": [
                        "Device: Transcutaneous vibro-acoustic device"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DEVICE",
                    "name": "Transcutaneous vibro-acoustic device",
                    "description": "Wearable device which sends low-frequency sound vibrations through the skin.",
                    "armGroupLabels": [
                        "Parkinson's Disease"
                    ],
                    "otherNames": [
                        "Apollo Neuro"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Average Nighttime Heart Rate Variability",
                    "description": "Average heart rate variability during the night, as measured by Oura ring device (measured in s).",
                    "timeFrame": "after 90-120 days of intervention"
                },
                {
                    "measure": "Paced Auditory Serial Addition Test score",
                    "description": "A measure of cognitive function that assesses auditory information processing speed and flexibility, scored as the total number correct out of 60. Higher scores indicate better performance.",
                    "timeFrame": "after 90-120 days of intervention"
                },
                {
                    "measure": "Spielberger State-Trait Anxiety Inventory score",
                    "description": "40-item questionnaire to assess anxiety. Scores range from 40-160 with higher scores indicating greater severity of anxiety.",
                    "timeFrame": "after 90-120 days of intervention"
                },
                {
                    "measure": "Hamilton Anxiety Scale score",
                    "description": "14-item questionnaire to evaluate severity of anxiety symptoms. Scores range from 0-56, with higher scores indicating greater severity of anxiety.",
                    "timeFrame": "after 90-120 days of intervention"
                },
                {
                    "measure": "Hamilton Depression Scale score",
                    "description": "17-item questionnaire to assess the severity of depression symptoms. Scores range from 0-61, with higher scores indicating more severe depression.",
                    "timeFrame": "after 90-120 days of intervention"
                },
                {
                    "measure": "Beck Depression Inventory score",
                    "description": "21-item scale to evaluate the severity of depression symptoms. Scores range from 0-63, with higher scores indicating more severe depression.",
                    "timeFrame": "after 90-120 days of intervention"
                },
                {
                    "measure": "Beck Anxiety Inventory score",
                    "description": "21-item questionnaire to assess the severity of anxiety. Scores range from 0-63, with higher scores indicating greater anxiety.",
                    "timeFrame": "after 90-120 days of intervention"
                },
                {
                    "measure": "Geriatric Depression Scale score",
                    "description": "15-item questionnaire scored from 0-15, with greater scores indicating greater severity of depression.",
                    "timeFrame": "after 90-120 days of intervention"
                },
                {
                    "measure": "Short Activities-specific Balance Confidence Scale score",
                    "description": "16-item scale to assess confidence in balance while performing different tasks. Scores range from 0-100 with greater scores indicating greater confidence.",
                    "timeFrame": "after 90-120 days of intervention"
                },
                {
                    "measure": "New Freezing of Gait Questionnaire score",
                    "description": "9-item questionnaire evaluating the severity of freezing of gait. Scores range from 0-29, with higher scores indicating more severe freezing of gait.",
                    "timeFrame": "after 90-120 days of intervention"
                },
                {
                    "measure": "Instrumental Activities of Daily Living Scale score",
                    "description": "8-item questionnaire to assess functional independence. Scores range from 0-8, with higher scores indicating higher functioning.",
                    "timeFrame": "after 90-120 days of intervention"
                },
                {
                    "measure": "Insomnia Severity Index score",
                    "description": "7-item scale to assess severity of insomnia. Scores range from 0-28, with higher scores indicating greater severity of insomnia.",
                    "timeFrame": "after 90-120 days of intervention"
                },
                {
                    "measure": "Epworth Sleepiness Scale score",
                    "description": "8-item scale to assess daytime sleepiness. Scores range from 0-24, with higher scores indicating greater daytime sleepiness.",
                    "timeFrame": "after 90-120 days of intervention"
                },
                {
                    "measure": "Fatigue severity Scale score",
                    "description": "9-item scale to measure the severity of fatigue. Scores range from 9-63, with higher scores indicating greater severity of fatigue.",
                    "timeFrame": "after 90-120 days of intervention"
                },
                {
                    "measure": "Perceived Stress Scale score",
                    "description": "10-item questionnaire to evaluate perceived levels of stress. Scores range from 0-40, with greater scores indicating greater perceived stress.",
                    "timeFrame": "after 90-120 days of intervention"
                },
                {
                    "measure": "Short Fall Efficacy Scale International score",
                    "description": "7-item questionnaire to evaluate fear of falling. Scores range from 7-28 with greater scores indicating greater fear of falling.",
                    "timeFrame": "after 90-120 days of intervention"
                },
                {
                    "measure": "Fatigue Visual Analogue Scale score (Alternate form)",
                    "description": "Scored from 0-100, with higher score indicating greater fatigue.",
                    "timeFrame": "after 90-120 days of intervention"
                },
                {
                    "measure": "Mayo Sleep Questionnaire Score on item 8",
                    "description": "Item 8 on the Mayo Sleep Questionnaire asks the participant to rate their general level of alertness over the past 3 weeks on a scale from 0 to 10, with 0 indicating they sleep all day and 10 indicating they are fully and normally awake.",
                    "timeFrame": "after 90-120 days of intervention"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosed with Parkinson's Disease (Hoehn and Yahr stage 2 or higher)\n* Individuals on or off dopaminergic therapy\n* Present of anxiety or panic disorder\n* Fear of falling\n* Understanding of use and care of smart phones and devices\n\nExclusion Criteria:\n\n* Presence of significant dementia\n* Disorders which may resemble PD, such as dementia with Lewy bodies, vascular dementia, normal pressure hydrocephalus, multiple system atrophy, corticobasal ganglionic degeneration, or toxic causes of parkinsonism.\n* Patients with a cardiac pacemaker\n* History of brain surgery or placement of a deep brain stimulator\n* Psoriasis vulgaris (or other inflammatory skin condition) on or near skin where the vibro-acoustic device and sleep tracking ring will be donned.\n* Patients on beta-blockers, benzodiazepines, antipsychotics, and stimulants (except for the treatment of attention deficit disorder/ADHD).\n* Pregnancy\n* Patients who begin cognitive behavioral therapy or a selective serotonin reuptake inhibitor (SSRI) medication for an anxiety disorder or other psychiatric disorder after the baseline clinical assessment.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "40 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Jacqueline Caswell",
                    "role": "CONTACT",
                    "phone": "734-936-0630",
                    "email": "jcaswel@med.umich.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Prabesh Kanel, PhD",
                    "affiliation": "University of Michigan",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Domino's Farms",
                    "status": "RECRUITING",
                    "city": "Ann Arbor",
                    "state": "Michigan",
                    "zip": "48105",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Prabesh Kanel, PhD",
                            "role": "CONTACT",
                            "phone": "734-998-8422",
                            "email": "prabeshk@med.umich.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.27756,
                        "lon": -83.74088
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000010300",
                    "term": "Parkinson Disease"
                }
            ],
            "ancestors": [
                {
                    "id": "D000020734",
                    "term": "Parkinsonian Disorders"
                },
                {
                    "id": "D000001480",
                    "term": "Basal Ganglia Diseases"
                },
                {
                    "id": "D000001927",
                    "term": "Brain Diseases"
                },
                {
                    "id": "D000002493",
                    "term": "Central Nervous System Diseases"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                },
                {
                    "id": "D000009069",
                    "term": "Movement Disorders"
                },
                {
                    "id": "D000080874",
                    "term": "Synucleinopathies"
                },
                {
                    "id": "D000019636",
                    "term": "Neurodegenerative Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M13213",
                    "name": "Parkinson Disease",
                    "asFound": "Parkinson's Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4324",
                    "name": "Anxiety Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M22494",
                    "name": "Parkinsonian Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M25603",
                    "name": "Ganglion Cysts",
                    "relevance": "LOW"
                },
                {
                    "id": "M16358",
                    "name": "Synovial Cyst",
                    "relevance": "LOW"
                },
                {
                    "id": "M4774",
                    "name": "Basal Ganglia Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5204",
                    "name": "Brain Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5742",
                    "name": "Central Nervous System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M12029",
                    "name": "Movement Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M2217",
                    "name": "Synucleinopathies",
                    "relevance": "LOW"
                },
                {
                    "id": "M21558",
                    "name": "Neurodegenerative Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                }
            ]
        }
    },
    "hasResults": false
}